BTG Licenses Alzheimer's Compounds To Senexis And Co-Invests £1 Million With The Wellcome Trust

07-Feb-2006

BTG plc and Senexis Limited announced that BTG has exclusively licensed its novel inhibitors of amyloid-induced toxicity and neuroinflammation to Senexis. These compounds may be useful in the treatment of Alzheimer's disease and other amyloid-based diseases. BTG will receive milestones payments as the compounds progress though development and future royalties on eventual sales. The first milestones will be triggered by candidate selection and approval to commence clinical studies.

BTG and the technology transfer division of the Wellcome Trust also announced that they have each invested £500,000 into Senexis to enable the company to progress preclinical development of its small molecule Alzheimer's programmes. BTG and the Wellcome Trust provided initial funding of £1.4 million to Senexis in November 2002.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

AMRI Hires Director of In Vitro Biology in Singapore

Action Pharma reports positive results in a proof of concept phase IB study in obese human volunteers treated with AP1030

Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist - Company Anticipates Initiating Phase 2a Studies by Early 2012

Elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board

Galapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeutics

Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor

RIKEN: Discovery of DNA Silencing Mechanism Reveals How Plants Protect Their Genome

Novasep invests EUR 30 million to build world's largest chromatography plant for the pharmaceutical industry - New plant on its Mourenx, France site to produce a large volume commercial API

Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy - £10m in milestone payments received from GlaxoSmithKline

KINAXO Biotechnologies receives 1 million EUR funding to quantify drug interactions with cellular protein targets

Effectiveness of drug to improve natriuretic peptide levels for chronic heart failure

Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications